Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 12401472

Tryptophan, mood, and cognitive function.

Wim J Riedel·Tineke Klaassen·Jeroen A J Schmitt
View original source ↗Export metadata ↓

Abstract

In separate experiments we investigated the duration of the effects of acute tryptophan depletion (ATD) on mood and cognition. The results showed that ATD's effects consist of lowering of mood only in subjects with a family history of unipolar depression. A specific impairment of memory consolidation was seen in all subjects. In subjects without any vulnerability for mood disorders, performance on so-called 'frontal tasks,' measuring higher attentional functions tended to improve after ATD. The effects of ATD on mood and cognition were manifest as long as biochemical indices of low tryptophan remained low. In conclusion, ATD is a model for impairment of memory, next to being a model of mood disorders in vulnerable subjects. Moreover, ATD could be used as a challenge to demonstrate individual vulnerability of the serotonergic system.

Explore related subjects

AffectAttentionCognitionCognition DisordersDepressive DisorderHumansMemoryMemory DisordersMood DisordersSerotoninTryptophanJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Wim J Riedel, Tineke Klaassen, Jeroen A J Schmitt. 2002. Tryptophan, mood, and cognitive function.. https://doi.org/10.1016/s0889-1591(02)00013-2

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2005

Emotional disclosure for whom? A study of vagal tone in bereavement.

Recent investigations have shown little evidence that written disclosure benefits bereaved individuals over a control condition. The present study hypothesized that the effectiveness of written disclosure for bereavement may be moderated by vagal tone, as indexed by respiratory sinus arrhythmia (RSA). Vagal tone has been identified as an important individual difference in depression. The present study investigated 35 bereaved participants in a longitudinal design, with participants writing each week for 3 weeks, and then participating in follow-up sessions 1 week and 1 month later. As with previous studies, bereaved participants showed improvement, although no differential improvement was seen in the emotional Disclosure group compared to a Control writing group. As hypothesized, however, those participants with the highest RSA benefited most from the written disclosure, while RSA level did not predict outcome in the control condition. Future research should investigate whether vagal tone moderates the impact of written disclosure for non-bereaved individuals.

Affect↗
PubMed2005

The effect of the decreased safety behaviors on anxiety and negative thoughts in social phobics.

In order to examine the effect of the decreased safety behaviors on social anxiety and negative thoughts and explore the mechanism underlying this effect, this study compared three types of exposure namely, exposure with decreased safety behaviors under cognitive rationale, exposure with decreased safety behaviors under extinction rationale, and exposure with no change in safety behavior. Forty-five social phobics were randomly assigned to one of three exposure groups. Results showed that exposure with decreased safety behaviors under cognitive rationale produced significantly greater reductions in anxiety and belief ratings for feared outcomes than exposure with decreased safety behaviors under extinction rationale and exposure with no change in safety behaviors. These results imply that exposure could be more effective if social phobics are encouraged to drop their safety behaviors in the feared social situation, and that the cognitive process of disconfirmation of negative thoughts is the critical element in determining effectiveness of decreased safety behaviors.

Affect↗
PubMed2005

Tamoxifen fails to affect central serotonergic tone but increases indices of anxiety in female rhesus macaques.

The selective estrogen receptor modulator (SERM), tamoxifen, effectively slows the progression of estrogen-positive breast cancer and aids in the prevention of cancer in at-risk women. Tamoxifen is well characterized with regards to its effects on breast cancer, but its effects on other estrogen-related systems, particularly neural circuits regulating brain function and mood, are poorly understood. Using ovariectomized rhesus monkeys, we examined the effects of tamoxifen, with and without estrogen replacement therapy (ERT), on social behavior and central serotonin (5HT) systems thought to influence these behaviors. Relative to placebo treatments, estrogen treatment increased serotonergic tone, based on response in prolactin and cortisol to fenfluramine, a 5HT releasing agent. Tamoxifen neither blocked nor enhanced this effect, indicating it to be neither an antagonist nor an agonist on serotonergic activity. In contrast, CSF measures of the 5HT metabolite, 5HIAA, were not significantly affected by treatment. Tamoxifen-treated animals showed increases in measures of anxiety, compared with ERT-treated animals, suggesting that this SERM may be anxiogenic. Co-treatment with estrogen attenuated the anxiogenic properties of tamoxifen. These data show that tamoxifen administration increased anxiety levels, but the affect was not associated with differences in central levels of the serotonin tone.

Affect↗